Account
Insider Insights
17.08.2023
Managed entry agreements: €195m saved by the Ita...

MEAs resulted in 195.2 million of savings for the Italian healthcare system, according to AIFA’s M...

Read more
Insider Insights
24.02.2023
The EU has a new project to find payment models fo...

Project to help the EU develop new pricing and payment models to fund high-priced drugs and relieve ...

Read more
Insider Insights
25.01.2023
AstraZeneca/Daiichi Sankyo’s Enhertu has been re...

NICE have recommended Enhertu for the treatment of HER2-positive breast cancer within a managed acce...

Read more
Case Study
01.01.2023
Enhancing Managed Entry Agreements (MEA)

Our client wanted to develop a training programme to help their employees learn about the value of M...

Read more
News
16.11.2022
PMA Insights: Week 46 SPECIAL EDITION ISPOR 2022 R...

We summarise the ISPOR Europe 2022 conference including plenary sessions on HTA, patient-centered re...

Read more
Publications
12.10.2022
ISPOR 2022: Could Netflix Based Subscription Model...

We analyse subscription-based agreements for antibiotics in Europe to understand how it may address ...

Read more
Insider Insights
06.04.2022
Cancer report recommends access to new treatments

The report looks at how differences in cancer survival rates between the UK and other countries have...

Read more
Insider Insights
01.02.2022
Orphan drugs undergo early benefit assessment

According to the Institute for Quality and Efficiency in Health Care orphan drugs should undergo ear...

Read more
Articles
28.04.2021
Managed access agreements NICE process

The highly specialised technologies (HST) process was introduced in 2013 for the purpose of evaluati...

Read more
Articles
24.04.2020
What are Managed Entry Agreements

Arrangements made between manufacturers and payers which are being implemented for innovative treatm...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.